Background {#Sec1}
==========

For most solid cancers, the 7^th^ edition of the American Joint Committee on Cancer (AJCC) TNM staging system accurately prognosticates outcome with lower stage cancers having better prognosis than higher stage cancers \[[@CR1]\]. However, colon cancer is one of the few exceptions. For stage IIB/C and stage IIIA, there exists a survival paradox \[[@CR2]--[@CR5]\]; the 5-year overall survival for patients with stage IIIA is approximately 70 % versus 46--61 % for stage IIB/C \[[@CR1]\]. Such a paradox is attributed to several factors according to previous studies, such as stage migration due to inadequate nodal sampling or lack of systemic therapy for stage IIB/C \[[@CR2], [@CR6]\]. We hypothesize that stage IIB/C is inherently more aggressive than stage IIIA, even after adjusting for receipt of chemotherapy and adequate nodal sampling. We propose to assess the simultaneous contribution of lymph node dissection and receipt of post-surgery chemotherapy to this survival paradox.

Methods {#Sec2}
=======

Data Source {#Sec3}
-----------

The nationally recognized National Cancer Data Base (NCDB) is a joint project of the Commission of Cancer (CoC) of the American College of Surgeons and the American Cancer Society. More than 1500 CoC-accredited facilities in the U.S. contribute clinical information to the database. Approximately 70 % of newly diagnosed cancer cases in the U.S and 30 million historical records are captured in the database (<https://www.facs.org/quality-programs/cancer/ncdb/puf>). The data in the Participant User File (PUF) were de-identified and in compliance with the privacy requirements of the Health Insurance Portability and Accountability Act (HIPAA). The study was exempted from Institutional Review Board (IRB) approval by the Louisiana State University Health Sciences Center-Shreveport.

Study population {#Sec4}
----------------

A cohort of 34,999 cases of stage IIIA or stage IIB/C colon cancer cases (ICD-0-3; C18.0, C18.2 to C.18.9) diagnosed in 2003--2012 in the NCDB were analyzed to determine significant factors associated with 5-year overall survival (OS). Patients were staged based on the 6^th^ and 7^th^ edition of the AJCC/TNM staging system \[[@CR1]\]. Patients were further divided into six subgroups based on number of lymph nodes (LNs) dissected and status of chemotherapy use: (1) Stage IIIA + chemotherapy, (2) Stage IIB/C, ≥ 12 LNs + chemotherapy, (3) Stage IIB/C, \< 12 LNs + chemotherapy, (4) Stage IIIA, no chemotherapy, (5) Stage IIB/C, ≥ 12 LNs, no chemotherapy, and (6) Stage IIB/C, \< 12 LNs, no chemotherapy.

According to the NCDB's PUF dictionary \[[@CR7]\], comorbidity was reported as Charlson/Deyo score: 0, 1 or 2 \[[@CR8], [@CR9]\]. Age at diagnosis, race, facility type, facility location, urban/rural, insurance status, income and education levels for each patient's area of residence, comorbid conditions, anatomic site, tumor grade, surgical margin status, chemotherapy, and number of lymph nodes retrieved were variables selected for evaluation. NCDB does not have information on cause-specific survival and therefore, overall survival was calculated based on death from all causes.

Statistical Analysis {#Sec5}
--------------------

We calculated the propensity scores by stage IIB/C and stage IIIA using a multivariable logistic regression model. Only cases with matched scores based on potential confounders (i.e., age, race, distance from cancer reporting facility, facility type, facility location, rural/urban, insurance, income, education, comorbidity, primary site, grade, and surgical margins) were included in the multivariable analysis. The purpose of this approach was to ensure that stage IIB/C and stage IIIA cases were comparable to reduce potential confounder effect. Descriptive statistics for the different variable were presented. Univariable analysis of each variable was performed using chi-square test for categorical data and ANOVA for numerical data. The Kaplan-Meier method was used for survival analysis. Univariable Cox proportional hazard regression was used to identify factors significantly associated with the risk of death for all causes. Multivariable Cox proportional hazards regression analysis was used to determine independent significant factors associated with the risk of death for all causes, and hazard ratios (HR) and confidence intervals (CI) were calculated. Insurance status, income and education levels for each patient's area of residence were also adjusted in the multivariable analysis. Results are based on adjusted variables. A *p*-value ≤ 0.05 was considered statistically significant. All statistical analyses were performed using SAS Version 9.4 statistical software, (SAS Institute Inc., Cary, NC, U.S.A., 2013).

Results {#Sec6}
=======

The median follow-up was 39 months. Figure [1](#Fig1){ref-type="fig"} demonstrates the Kaplan-Meier OS curve for stage IIB, stage IIC, and stage IIIA. Note that there is a significant survival difference between stage IIB/C and stage IIIA (*P* \< 0.0001), although there was no significant survival difference between stage IIB and stage IIC (*P* = 0.46). Figure [2](#Fig2){ref-type="fig"} demonstrates the Kaplan-Meier OS curve for the 6 subgroups which were defined by the number lymph nodes retrieved (\<12 LNs vs ≥12 LNs) and whether or not systemic chemotherapy was given. For the entire cohort, the 5-year OS rate was 73.5 % for stage IIIA and 51.1 % for stage IIB/C. For the subgroups, the 5-year OS are 84.1 % for stage IIIA plus chemotherapy, 70.8 % for stage IIB/C with ≥ 12 LNs plus chemotherapy, 53.9 % for stage IIB/C \< 12 LNs plus chemotherapy, 49.5 % for stage IIIA without chemotherapy, 43.7 % for stage IIB/C ≥ 12 LNs without chemotherapy, and 27.7 % for stage IIB/C \< 12 LNs without chemotherapy (*P* \< 0.0001). The median survival has not been reached by the end of follow up (132 months) for stage IIIA with chemotherapy; it was 122.6 months for stage IIB/C, ≥ 12 LNs with chemotherapy, 72.5 months for stage IIB/C, \< 12 LNs with chemotherapy, 58.9 months for stage IIIA without chemotherapy, 46.5 months for stage IIB/C, ≥ 12 LNs without chemotherapy, and 23.0 months for stage IIB/C, \< 12 LNs without chemotherapy.Fig. 1Overall Survival for Stage IIB/C and Stage IIIA: Note that there is a statistically significant survival difference between stage IIIA and stage IIB/C (*P* \< 0.0001). However, there is no significant difference between stage IIB and stage IIC (*P* = 0.46)Fig. 2Overall Survival for the Six Subgroups of Patients with Stage IIB/C and Stage IIIA Colon Cancer. The 5-year OS are 84.1 % for stage IIIA plus chemotherapy, 70.8 % for stage IIB/C with ≥ 12 LNs plus chemotherapy, 53.9 % for stage IIB/C \< 12 LNs plus chemotherapy, 49.5 % for stage IIIA without chemotherapy, 43.7 % for stage IIB/C ≥ 12 LNs without chemotherapy, and 27.7 % for stage IIB/C \< 12 LNs without chemotherapy (*P* \< 0.0001). The median survival has not been reached by the end of follow up (132 months) for stage IIIA with chemotherapy, 122.6 months for stage IIB/C, ≥ 12 LNs with chemotherapy, 72.5 months for stage IIB/C, \< 12 LNs with chemotherapy, 58.9 months for stage IIIA without chemotherapy, 46.5 months for stage IIB/C, ≥ 12 LNs without chemotherapy, and 23.0 months for stage IIB/C, \< 12 LNs without chemotherapy

The poorest survival subgroup was stage IIB/C with \< 12 LNs retrieved and without receipt of adjuvant chemotherapy. Note that even when patients with stage IIB/C received optimal treatment (≥12 LNs retrieved and receipt of chemotherapy), their OS remains significantly lower than those with stage IIIA who had chemotherapy (Fig. [2](#Fig2){ref-type="fig"}).

Table [1](#Tab1){ref-type="table"} compares the demographic and therapeutic characteristics of stage IIB/C and stage III A before and after matching. Note that the two groups were fairly balanced after matching. Table [2](#Tab2){ref-type="table"} is a univariable analysis of factors associated with survival and Table [3](#Tab3){ref-type="table"} is the multivariable analysis based on the adjusted matched analysis. Note that stage IIB/C is an independent predictor of worse outcome compared to stage IIIA. T-stage and N-stage were not included because they were co-linear with stage of disease. Other independent factors associated with high hazard ratio include less than 12 lymph nodes retrieved, lack of receipt of chemotherapy, and positive margins. Before including LN dissection and chemotherapy in the multivariable model, the HR of stage IIB/C versus stage IIIA was 1.76 (95 % CI: 1.68--1.85). After adjusting for LN dissection and chemotherapy in addition to the adjustment of clinical variables included in Table [3](#Tab3){ref-type="table"}, the HR was reduced to 1.51 (95 % CI: 1.44--1.59). Additional adjustment of demographic variables in Table [3](#Tab3){ref-type="table"} did not change the HR much (HR = 1.52; 95 % CI: 1.44--1.60).Table 1Comparison of demographic and therapeutic characteristics of stage IIB/C and stage IIIABefore matchingAfter matchingVariableStage IIB/CStage IIIA*P*Stage IIB/CStage IIIA*P*No. of patients (%)18,609 (53.2)16,390 (46.8)11,409 (50.0)11,409 (50.0)Age\<.00010.94 18--491,678 (9.0)1424 (8.7)935 (8.2)920 (8.1) 50--644,628 (24.9)5284 (32.2)2,979 (26.1)3,016 (26.4) 65--744,368 (23.5)4419 (27.0)2,957 (25.9)2,956 (25.9) 75 and more7,935 (42.6)5263 (32.1)4,538 (39.8)4,517 (39.6)Distance from cancer reporting facility0.060.58 \<50 miles16,909 (92.9)15,015 (93.4)10,630 (93.2)10,651 (93.4) ≥50 miles1,303 (7.2)1,066 (6.6)779 (6.8)758 (6.6)Race/Ethnicity\<.00010.93 White15,964 (86.5)13,450 (82.8)9,785 (85.8)9,770 (85.6) Black1,965 (10.6)2,197 (13.5)1,283 (11.3)1,308 (11.5) American Indian, Aleutian, or Eskimo53 (0.3)36 (0.2)27 (0.2)31 (0.3) Asian or Pacific Islander390 (2.1)456 (2.8)261 (2.3)251 (2.2) Other89 (0.5)100 (0.6)53 (0.5)49 (0.4)Facility Type0.020.90 Community cancer program2,715 (14.6)2,239 (13.7)1,565 (13.7)1,588 (13.9) Comprehensive community cancer center11,044 (59.4)9,700 (59.2)6,815 (59.7)6,804 (59.6) Academic research program4,825 (25.9)4,432 (27.0)3,029 (26.6)3,017 (26.4) Other specified types of cancer program25 (0.1)19 (0.1)Facility Location\<.00010.99 New England1,335 (7.2)886 (5.4)678 (5.9)692 (6.1) Mid Atlantic2,971 (16.0)2,402 (14.7)1,814 (15.9)1,809 (15.9) South Atlantic3,835 (20.6)3,715 (22.7)2,352 (20.6)2,391 (21.0) East North Central3,580 (19.2)3,127 (19.1)2,174 (19.1)2,201 (19.3) East South Central1,162 (6.2)1,186 (7.2)788 (6.9)786 (6.9) West North Central1,555 (8.4)1,333 (8.1)1,035 (9.1)1,002 (8.8) West South Central1,487 (8.0)1,391 (8.5)942 (8.3)938 (8.2) Mountain779 (4.2)678 (4.1)440 (3.9)438 (3.8) Pacific1,905 (10.2)1,672 (10.2)1,186 (10.4)1,152 (10.1)Urban/Rural Location0.050.96 Metro ≥1 million9,488 (53.0)8,380 (53.1)6,039 (52.9)6,028 (52.8) Metro 250 k to 1 million3,863 (21.6)3,556 (22.5)2,539 (22.3)2,554 (22.4) Urban \<250 k1,766 (9.9)1,516 (9.6)1,104 (9.7)1,112 (9.8) Urban ≥ 20 k adjacent metro731 (4.1)657 (4.2)460 (4.0)476 (4.2) Urban ≥ 20 k not adjacent metro262 (1.5)221 (1.4)182 (1.6)175 (1.5) Urban \<20 k adjacent metro957 (5.4)751 (4.8)577 (5.1)572 (5.0) Urban \<20 k not adjacent metro454 (2.5)387 (2.5)286 (2.5)258 (2.3) Rural \<2500 adjacent metro164 (0.9)169 (1.1)108 (1.0)109 (1.0) Rural \<2500 not adjacent metro212 (1.2)154 (1.0)114 (1.0)125 (1.1)Comorbidities\<.00010.61 012,872 (69.2)11,665 (71.2)7,905 (69.3)7,962 (69.8) 14,185 (22.5)3,537 (21.6)2,576 (22.6)2,513 (22.0) 21,552 (8.3)1,188 (7.3)928 (8.1)934 (8.2)Primary Site\<.00010.99 Cecum4,917 (26.4)3,941 (24.1)3,077 (27.0)3,077 (27.0) Ascending Colon2,876 (15.5)3,140 (19.2)1,969 (17.3)1,992 (17.5) Hepatic Flexure748 (4.0)608 (3.7)473 (4.2)461 (4.0) Transverse Colon2,061 (11.1)1,154 (7.0)1,031 (9.0)991 (8.7) Splenic Flexure786 (4.2)366 (2.2)312 (2.7)327 (2.9) Descending Colon1,161 (6.2)960 (5.9)705 (6.2)706 (6.2) Sigmoid Colon5,324 (28.6)5,756 (35.1)3,524 (30.9)3,535 (31.0) Overlapping Lesions369 (2.0)140 (0.9)120 (1.1)121 (1.1) Not Otherwise Specified367 (2.0)325 (2.0)198 (1.7)199 (1.7)Grade\<.00010.87 Well differentiated1,506 (8.4)1,779 (11.4)1,087 (9.5)1,084 (9.5) Moderately differentiated11,868 (66.0)11,226 (71.9)8,007 (70.2)8,049 (70.6) Poorly differentiated4,004 (22.3)2,381 (15.3)2,084 (18.3)2,059 (18.1) Undifferentiated, anaplastic611 (3.4)230 (1.5)231 (2.0)217 (1.9)Surgical Margins\<.00010.87 No residual tumor14992 (82.6)16,012 (98.8)11,243 (98.6)11,246 (98.6) With Residual tumor3156 (17.4)190 (1.2)166 (1.5)163 (1.4)Regional Lymph Nodes Examined\<.0001\<.0001 0--114,399 (23.8)4,867 (29.9)2,422 (21.3)3,298 (29.0) 12--9014,101 (76.2)11,434 (70.1)8,944 (78.7)8,078 (71.0)Chemotherapy\<.0001\<.0001 None10,423 (58.7)4,807 (30.5)6,362 (58.4)3,659 (33.3) Yes7,335 (41.3)10,975 (69.5)4,525 (41.6)7,327 (66.7)Table 2Univariable analysis of factors associated with overall survivalBefore matchingAfter matchingVariableHR95 % CI*P*-valueHR95 % CI*P*-valueStage Stage IIB/C2.15(2.07, 2.24)\<.00011.70(1.62, 1.78)\<.0001 Stage IIIA1.00----1.00----Age 18--491.00----1.00---- 50--641.30(1.17, 1.45)\<.00011.41(1.22, 1.63)\<.0001 65--742.23(2.02, 2.48)\<.00012.48(2.16, 2.86)\<.0001 75 and more4.86(4.41, 5.37)\<.00015.12(4.47, 5.87)\<.0001Race/ Ethnicity White1.00----1.00---- Black0.96(0.91, 1.02)0.191.06(0.98, 1.14)0.14 American Indian, Aleutian, or Eskimo0.90(0.61, 1.33)0.600.93(0.58, 1.47)0.75 Asian or Pacific Islander0.55(0.47, 0.64)\<.00010.62(0.50, 0.75)\<.0001 Other0.63(0.46, 0.87)0.0050.64(0.41, 0.99)0.05Facility Type Community cancer program1.39(1.31, 1.48)\<.00011.40(1.30, 1.52)\<.0001 Comprehensive community cancer center1.21(1.16, 1.26)\<.00011.24(1.17, 1.31)\<.0001 Academic research program1.00----1.00----Facility Location New England1.08(0.99, 1.18)0.100.94(0.84, 1.06)0.32 Mid Atlantic1.07(0.99, 1.16)0.070.98(0.89, 1.08)0.68 South Atlantic1.06(0.99, 1.13)0.121.00(0.92, 1.09)0.98 East North Central1.10(1.03, 1.18)0.0081.04(0.95, 1.14)0.39 East South Central1.09(0.998, 1.20)0.051.08(0.97, 1.21)0.16 West North Central1.10(1.005, 1.19)0.041.04(0.94, 1.16)0.43 West South Central1.01(0.92, 1.11)0.800.99(0.89, 1.11)0.84 Mountain0.93(0.83, 1.04)0.200.87(0.75, 1.01)0.06 Pacific1.00----1.00----Urban/Rural Location Metro ≥1 million1.00----1.00---- Metro 250 k to 1 million1.07(1.02, 1.12)0.0081.09(1.03, 1.15)0.004 Urban \<250 k1.07(1.004, 1.14)0.041.06(0.98, 1.14)0.17 Urban ≥ 20 k adjacent metro1.10(1.002, 1.21)0.0461.10(0.98, 1.24)0.09 Urban ≥ 20 k not adjacent metro1.04(0.89, 1.22)0.651.05(0.87, 1.26)0.63 Urban \<20 k adjacent metro1.13(1.04, 1.23)0.0061.06(0.95, 1.18)0.30 Urban \<20 k not adjacent metro1.23(1.10, 1.38)0.00051.32(1.15, 1.52)0.0001 Rural \<2500 adjacent metro1.02(0.85, 1.24)0.810.88(0.68, 1.14)0.33 Rural \<2500 not adjacent metro1.12(0.94, 1.33)0.211.06(0.85, 1.32)0.58Comorbidities 01.00----1.00---- 11.46(1.40, 1.53)\<.00011.49(1.42, 1.58)\<.0001 22.29(2.16, 2.42)\<.00012.29(2.13, 2.46)\<.0001Primary Site Cecum1.00----1.00---- Ascending Colon0.96(0.91, 1.02)0.151.04(0.97, 1.11)0.30 Hepatic Flexure0.97(0.88, 1.07)0.510.95(0.84, 1.07)0.39 Transverse Colon1.07(0.997, 1.14)0.060.93(0.85, 1.02)0.11 Splenic Flexure1.07(0.96, 1.18)0.230.90(0.77, 1.04)0.15 Descending Colon0.85(0.78, 0.93)0.00030.85(0.77, 0.95)0.003 Sigmoid Colon0.76(0.72, 0.80)\<.00010.82(0.77, 0.87)\<.0001 Overlapping Lesions1.19(1.03, 1.38)0.020.80(0.62, 1.03)0.08 Not Otherwise Specified1.14(1.004, 1.29)0.041.13(0.95, 1.33)0.17Grade Well differentiated1.00----1.00---- Moderately differentiated1.09(1.02, 1.16)0.011.04(0.96, 1.13)0.37 Poorly differentiated1.39(1.29, 1.50)\<.00011.11(1.01, 1.22)0.03 Undifferentiated, anaplastic1.74(1.53, 1.97)\<.00011.23(1.02, 1.48)0.03Surgical Margins No residual tumor1.00----1.00---- With Residual tumor1.91(1.81, 2.02)\<.00011.24(1.03, 1.49)0.02Readmission within 30 days of Surgery Not readmitted1.00----1.00---- Readmitted1.15(1.08, 1.22)\<.00011.13(1.05, 1.22)0.002Regional Lymph Nodes Examined 0--111.34(1.29, 1.39)\<.00011.29(1.23, 1.35)\<.0001 12--901.00----1.00----Chemotherapy Yes1.00----1.00---- No3.55(3.41, 3.70)\<.00013.49(3.32, 3.67)\<.0001Table 3Multivariable analysis (After Matching) of factors associated with overall survivalVariableHR95 % CI*P*-valueStage Stage IIB/C1.52(1.44,1.60)\<.0001 Stage IIIA1.00----Age 18--49------ 50--641.24(1.06, 1.44)0.006 65--741.70(1.44, 1.99)\<.0001 75 and more2.85(2.43, 3.35)\<.0001Race/Ethnicity White1.00---- Black1.18(1.09, 1.28)\<.0001 American Indian, Aleutian, or Eskimo1.15(0.71, 1.87)0.57 Asian or Pacific Islander0.76(0.62, 0.94)0.01 Other0.73(0.45, 1.18)0.20Facility Type Community cancer program1.29(1.18, 1.40)\<.0001 Comprehensive community cancer center1.15(1.08, 1.22)\<.0001 Academic research program1.00----Facility Location New England1.00(0.88, 1.14)0.98 Mid Atlantic0.99(0.90, 1.10)0.91 South Atlantic0.95(0.87, 1.05)0.32 East North Central0.95(0.87, 1.05)0.31 East South Central0.98(0.87, 1.11)0.79 West North Central1.02(0.91, 1.15)0.68 West South Central0.96(0.85, 1.08)0.46 Mountain0.91(0.79, 1.06)0.25 Pacific1.00----Urban/Rural Location Metro ≥1 million1.00---- Metro 250 k to 1 million1.02(0.96, 1.08)0.56 Urban \<250 k0.95(0.87, 1.03)0.22 Urban ≥ 20 k adjacent metro0.98(0.87, 1.11)0.75 Urban ≥ 20 k not adjacent metro0.89(0.73, 1.08)0.24 Urban \<20 k adjacent metro0.98(0.87, 1.10)0.68 Urban \<20 k not adjacent metro1.10(0.94, 1.28)0.25 Rural \<2500 adjacent metro0.93(0.72, 1.21)0.57 Rural \<2500 not adjacent metro0.90(0.71, 1.14)0.38Comorbidities 01.00---- 11.26(1.19, 1.33)\<.0001 21.65(1.53, 1.77)\<.0001Primary Site Cecum1.00---- Ascending Colon1.00(0.93, 1.08)0.99 Hepatic Flexure1.02(0.90, 1.16)0.72 Transverse Colon0.97(0.88, 1.06)0.45 Splenic Flexure1.16(0.99, 1.35)0.07 Descending Colon1.06(0.95, 1.19)0.31 Sigmoid Colon0.98(0.92, 1.05)0.58 Overlapping Lesions0.92(0.70, 1.20)0.54 Not Otherwise Specified1.39(1.17, 1.66)0.0002Readmission within 30 days of Surgery Not readmitted1.00---- Readmitted1.21(1.12, 1.31)\<.0001Grade Well differentiated1.00---- Moderately differentiated1.07(0.98, 1.16)0.12 Poorly differentiated1.20(1.09, 1.32)0.0002 Undifferentiated, anaplastic1.21(1.00, 1.47)0.05Regional Lymph Nodes Examined 0--111.30(1.23, 1.37)\<.0001 12--901.00----Chemotherapy Yes1.00---- No2.24(2.11, 2.37)\<.0001Surgical Margins No residual tumor1.00---- With Residual tumor1.56(1.29, 1.89)0.003

Discussion {#Sec7}
==========

Accurate cancer staging at the time of diagnosis assists clinicians to predict survival, impart prognostic information, and select the most effective treatments \[[@CR10]\]. The last three decades, the American Joint Committee on Cancer (AJCC) has undergone multiple iterations. AJCC 5^th^ edition cancer staging system had only four categories for colon cancer, based on tumor-node-metastasis (TNM) classification (Stages I, II, III, IV) \[[@CR11]\]. In 2002, AJCC 6^th^ edition subdivided stage II into IIA (T3N0) and IIB (T4N0) \[[@CR12]\], but in 2000, the colorectal working group subdivided T4 into T4a (tumor penetrates the surface of the visceral peritoneum) and T4b (tumor directly invades or is histologically adherent to other organs or structures) \[[@CR13]\] based on data that found that peritoneal involvement had an adverse outcome \[[@CR14]\]. The latest AJCC 7^th^ edition published in 2010 further refined colorectal cancer staging by dividing N1 into N1a (metastasis in 1 node) and N1b (metastasis in 2--3 nodes), and N2 into N2a (metastasis in 4--6 nodes) and N2b (metastasis in ≥ 7 nodes). Consequently, stage II becomes IIA (T3N0), IIB (T4aN0), or IIC (T4bN0) and stage III becomes IIIA (T1-2 N1, T1N2a), IIIB (T3-4 N1, T2-3N2a, T1-2N2b), and IIIC (T4aN2a, T3-T4aN2b, T4bN1-2) \[[@CR1]\].

Even with the latest iteration of AJCC, the OS for stage IIB/C remains lower than those with stage IIIA; the OS for stage IIB was 60.6 % versus 45.7 % for stage IIC and 67.2 to 73.7 % for stage IIIA \[[@CR1]\]. Several groups attributed the survival paradox to either stage migration or lack of receipt of systemic therapy \[[@CR2]--[@CR6]\]. The implication is that if those with stage IIB/C received adequate lymph node dissection and adjuvant chemotherapy, their survival would have been better than those with stage III disease. No studies have demonstrated whether such is the case. Because the assumption has not been challenged, there is little impetus to revise the TNM staging system to account for the survival paradox. However, given our large robust database, we were able to analyze our cohorts based not only on receipt of chemotherapy, but also on the number of lymph nodes retrieved. To our knowledge, ours is the first and the largest dataset that assesses how these two factors, when combined, contribute to the paradox. Surprisingly, we found that even when adequate lymph nodes were retrieved and chemotherapy was administered, the survival paradox persists. What this suggests is that T4N0 lesions (i.e. stage IIB/C) may be inherently more aggressive than stage IIIA, although further research is necessary to delineate the root cause of the poorer survival among them.

Positive margins portend a poor outcome \[[@CR15]\]. Inadequate resection of locally advanced lesions (i.e. T4) can lead to positive surgical margins, especially if an *en-bloc* resection was not performed \[[@CR16]\]. In our study, positive margins impart a 56 % increased risk of death compared to negative margins. What impact surgical margins have on the paradox for optimally treated patients with stage IIB/C colon cancer will be the subject of our next investigation.

The role of adjuvant chemotherapy for patients with resected stage II colon cancer remains controversial. The 5-year OS following definitive colectomy for stage II colon cancer is in the range of 85-89 % \[[@CR17]\]. Whether adjuvant systemic therapy can further improve this rate remains an area of intense investigation. Besides the QUASAR (Quick and Simple and Reliable) trial \[[@CR18]\], which was a phase III trial that found OS benefit for patients with Stage II colon cancer, multiple other randomized trials as well as meta-analysis found no such significant advantage with chemotherapy \[[@CR17], [@CR19]--[@CR25]\]. Although the commonly cited QUASAR trial (Quick and Simple and Reliable) showed an absolute improvement of 3.6 % for stage II colon cancer that received adjuvant therapy, the trial had several limitations \[[@CR18]\]. Approximately 8.5 % of 3,239 patients who were thought to have stage II colon cancer actually had stage I or III disease and almost 30 % had rectal cancer (many of these patients received radiation therapy) \[[@CR18]\]. To our knowledge, our analysis is the first to demonstrate a survival advantage of using adjuvant chemotherapy for stage II disease, but only for those with stage IIB/C colon cancer since we have 138,572 stage IIA patients in NCDB. Our data lend support to the American Society of Clinical Oncology's recommendation of postoperative chemotherapy for patients with T4 tumors \[[@CR26]\]. Of interest is that even when optimal treatment was rendered to those with stage IIB/C disease, their OS remains significantly lower than those with stage IIIA who had chemotherapy. Other factors that contribute to the survival paradox will need to be further investigated. Given our provocative data, we believe that randomized control studies are needed to determine whether there is a survival advantage of using adjuvant chemotherapy for stage II colon cancer.

One of the limitations of our study is the lack of recurrence data since this is not recorded in the NCDB. Additionally, we do not have specific causes of death and therefore it is plausible that deaths may not be related to cancer. We also do not have data on other factors such as microsatellite instability (MSI), preoperative CEA level, whether or not patients presented with obstruction or perforation, whether there was evidence of venous or perineural invasion, and whether blood transfusion had taken place, all of which are important prognosticators. However, our results are hypothesis-generating and can serve as a platform to further evaluate and explain the survival paradox.

Conclusions {#Sec8}
===========

Based on our analysis of nearly 35,000 patients, we confirmed that a survival paradox between Stage IIIA and Stage IIB/C colon cancer patients exists for cases diagnosed in 2003--2012 in the ACoS' hospitals. Although inadequate lymph nodes retrieved and lack of receipt of adjuvant chemotherapy contributes to stage IIB/C poor survival compared to stage IIIA, they themselves do not entirely explain the paradox. Further studies are necessary to determine other factors that also contribute to the paradox, including our hypothesis that stage IIB/C is inherently more aggressive than stage IIIA. Future iteration of AJCC staging of colon cancer should consider reconciling this paradox.
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